Clinical Trial Update: dnaJ Peptide for Relieving Rheumatoid Arthritis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the dnaJ Peptide for relief of symptoms in Rheumatoid Arthritis has completed (status: COMPLETED).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• dnaJ Peptide (dnaJ peptide)

Snippet

Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Conditions: Rheumatoid Arthritis | Phase 2 | Status: COMPLETED